Quantitative Investment Management LLC increased its holdings in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 108.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,176 shares of the company’s stock after buying an additional 3,741 shares during the period. Quantitative Investment Management LLC’s holdings in Astrazeneca were worth $1,360,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in the business. Mascoma Wealth Management LLC acquired a new position in shares of Astrazeneca in the first quarter worth $26,000. MV Capital Management Inc. acquired a new stake in shares of Astrazeneca in the fourth quarter valued at $26,000. Roxbury Financial LLC purchased a new position in Astrazeneca in the second quarter valued at $29,000. Reflection Asset Management purchased a new position in Astrazeneca in the fourth quarter valued at $31,000. Finally, Resources Management Corp CT ADV acquired a new position in Astrazeneca during the 1st quarter worth $35,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca Trading Down 0.3%
NYSE:AZN opened at $162.21 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. Astrazeneca Plc has a 1 year low of $145.79 and a 1 year high of $212.71. The stock has a market cap of $251.57 billion, a P/E ratio of 24.25, a P/E/G ratio of 1.41 and a beta of 0.26. The stock has a 50-day simple moving average of $170.95 and a 200-day simple moving average of $184.57.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. HSBC cut Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Finally, CICC Research initiated coverage on shares of Astrazeneca in a research note on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target for the company. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and a consensus price target of $206.67.
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
